GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » EV-to-FCF

BRAIN Biotech AG (XTER:BNN) EV-to-FCF : -28.88 (As of Jun. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BRAIN Biotech AG's Enterprise Value is €53.35 Mil. BRAIN Biotech AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.85 Mil. Therefore, BRAIN Biotech AG's EV-to-FCF for today is -28.88.

The historical rank and industry rank for BRAIN Biotech AG's EV-to-FCF or its related term are showing as below:

XTER:BNN' s EV-to-FCF Range Over the Past 10 Years
Min: -222.34   Med: -40.61   Max: -15.27
Current: -29.48

During the past 9 years, the highest EV-to-FCF of BRAIN Biotech AG was -15.27. The lowest was -222.34. And the median was -40.61.

XTER:BNN's EV-to-FCF is ranked worse than
100% of 842 companies
in the Chemicals industry
Industry Median: 19.69 vs XTER:BNN: -29.48

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-15), BRAIN Biotech AG's stock price is €2.72. BRAIN Biotech AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.370. Therefore, BRAIN Biotech AG's PE Ratio for today is At Loss.


BRAIN Biotech AG EV-to-FCF Historical Data

The historical data trend for BRAIN Biotech AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG EV-to-FCF Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -20.56 -16.70 -38.61 -13.53 -13.58

BRAIN Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.25 -18.33 -13.58 -16.59 -38.17

Competitive Comparison of BRAIN Biotech AG's EV-to-FCF

For the Specialty Chemicals subindustry, BRAIN Biotech AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG's EV-to-FCF Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's EV-to-FCF falls into.



BRAIN Biotech AG EV-to-FCF Calculation

BRAIN Biotech AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=53.349/-1.847
=-28.88

BRAIN Biotech AG's current Enterprise Value is €53.35 Mil.
BRAIN Biotech AG's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BRAIN Biotech AG  (XTER:BNN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BRAIN Biotech AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.72/-0.370
=At Loss

BRAIN Biotech AG's share price for today is €2.72.
BRAIN Biotech AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.370.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BRAIN Biotech AG EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines